Laura Balan Balan Acquires 3,500 Shares of Hikma Pharmaceuticals (LON:HIK) Stock

Key Points

• Laura Balan, an insider at Hikma Pharmaceuticals, acquired 3,500 shares of the company's stock at an average price of GBX 1,821, totaling £63,735.
• Hikma Pharmaceuticals' stock has a market capitalization of £5.09 billion and a current consensus rating of "Buy" from analysts with a target price averaging GBX 2,627.50.
• Recent analyst reports have seen target price decreases from major banks, including JPMorgan and Deutsche Bank, suggesting a more cautious outlook on the stock.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) insider Laura Balan Balan acquired 3,500 shares of the stock in a transaction on Friday, August 22nd. The stock was bought at an average price of GBX 1,821 per share, for a total transaction of £63,735.

Hikma Pharmaceuticals Price Performance

Shares of HIK stock traded up GBX 23 during trading hours on Wednesday, hitting GBX 1,843. 469,626 shares of the company's stock were exchanged, compared to its average volume of 1,007,437. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The firm has a market cap of £5.11 billion, a P/E ratio of 18.08, a P/E/G ratio of 2.38 and a beta of 0.41. The firm has a 50 day moving average of GBX 1,937.13 and a two-hundred day moving average of GBX 2,013.41. Hikma Pharmaceuticals PLC has a fifty-two week low of GBX 1,690 and a fifty-two week high of GBX 2,360.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on HIK shares. JPMorgan Chase & Co. decreased their target price on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a "buy" rating for the company in a report on Tuesday, August 12th. Finally, Jefferies Financial Group restated a "buy" rating and set a GBX 2,600 price target on shares of Hikma Pharmaceuticals in a report on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of GBX 2,627.50.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.